Specialty pharmaceutical company iX Biopharma has obtained export listing status for Xativa, its CBD (cannabidiol) sublingual wafer. 

In a press release on June 28, iX Biopharma announced Xativa’s inclusion in the Australian Register of Therapeutic Goods' (ARTG) list of drugs approved for export.

Pursuant to the approval, the company will commence supply of Xativa to Brazil, where it will distribute and market the product through local partners. 


To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook